Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Oct 1 · below the Ichimoku cloud · RSI 47 · MACD below its signal · at its 52-week low
None of the 29 investors followed here reported a position in NTRR in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NTRR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for NTRR.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 100.0 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 50.0 | -33.3 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 50.0 | -66.7 | 200.0 | -66.7 | 100.0 | 50.0 | -33.3 | 0.0 | -50.0 | −50.0% |
| 2024 | 0.0 | 0.0 | 0.0 | 33.3 | -25.0 | -33.3 | -50.0 | 100.0 | -50.0 | 0.0 | 0.0 | 100.0 | −33.3% |
| 2023 | 25.0 | -40.0 | 33.3 | -25.0 | 33.3 | 25.0 | 0.0 | -20.0 | 25.0 | -40.0 | 20.0 | -16.7 | −25.0% |
| 2022 | 0.8 | -25.6 | 33.3 | -50.0 | 0.0 | 16.7 | 28.6 | -22.2 | 0.0 | 0.0 | -14.3 | -33.3 | −66.7% |
| 2021 | 100.0 | 140.6 | -16.9 | -31.2 | -9.3 | -4.8 | -42.1 | 9.1 | 29.2 | -3.2 | -46.7 | -25.0 | −25.0% |
| 2020 | 14.3 | -25.0 | -50.0 | 0.0 | 900.0 | -40.0 | -11.1 | -18.7 | -30.8 | -5.6 | -11.8 | 113.3 | +128.6% |
| 2019 | -18.4 | -25.2 | -22.7 | -32.3 | -39.4 | -71.4 | 36.4 | -36.7 | -47.4 | -20.0 | -12.5 | 0.0 | −98.2% |
| 2018 | -6.1 | -13.1 | -19.4 | -32.3 | 10.5 | -10.2 | -1.1 | -1.9 | -33.1 | -7.1 | -40.4 | 2.1 | −83.8% |
| 2017 | 50.0 | -24.7 | -34.3 | -13.0 | -32.3 | -41.7 | -1.3 | -11.5 | 0.0 | 6.7 | -4.3 | 247.8 | −21.0% |
| 2016 | -41.0 | 11.6 | -19.3 | -19.8 | -17.6 | 4.2 | -24.0 | -8.8 | -9.6 | 6.4 | -32.0 | -8.8 | −84.9% |
| 2015 | -33.0 | -2.2 | -8.4 | -4.8 | -24.7 | -65.7 | 142.8 | 11.3 | -36.3 | -15.7 | 1.9 | 88.1 | −59.0% |
| 2014 | 173.0 | -26.7 | 8.3 | -37.0 | -23.7 | 3.4 | -20.5 | -30.6 | -27.8 | 23.7 | -12.3 | -31.7 | −68.3% |
| 2013 | 18.5 | -35.0 | 380.8 | -34.0 | -51.5 | -43.8 | -28.9 | 159.3 | -27.7 | -8.3 | -23.7 | -25.0 | −53.3% |
| 2012 | 87.5 | -55.6 | -82.0 | -27.9 | -53.8 | -48.3 | 90.3 | 5.9 | -16.0 | 13.3 | -4.2 | -40.8 | −97.2% |
| 2011 | -0.8 | -4.0 | −4.8% |
No analyst coverage for this instrument.
Neutra Corp. researches, develops, and provides hemp-derived products in the nutraceutical space in the United States. The company sells hemp-derived products, including products containing delta-8-THC and other cannabinoids, CBD sports creams, and other products. Neutra Corp. was incorporated in 2011 and is based in Houston, Texas.